Progress in gene therapy for hepatocellular carcinoma.docVIP

 PAGE \* MERGEFORMAT 12 Progress in gene therapy for hepatocellular carcinoma [Keywords:] Primary liver cancer, gene therapy, RNA interference Primary liver cancer (Primary hepatic carcinoma, PHC) is a common malignant tumor. At present the main treatment methods of PHC surgery, radiotherapy, chemotherapy and comprehensive treatment, but treatment is not satisfactory. As the molecular biology and immunological technology, gene therapy in the treatment of cancer and has broad prospects. gene therapy methods are two categories for gene correction and replacement, and the other for the gene addition, do not remove the abnormal gene, and exogenous gene through the integration of non-point to compensate for defects in gene function for therapeutic purposes. In this paper, progress in gene therapy of hepatocellular carcinoma are summarized below. 1 antisense gene therapy The occurrence of liver cancer development and progression of many cancer genes and growth factors highly expressed gene products, antisense nucleic acid transcription and translation level in blocking the abnormal expression of certain genes to cancer cells block the abnormal signal transduction, so that the normal differentiation of cancer cells into the orbit or induce apoptosis, thus inhibiting tumor growth. antisense genes, including antisense RNA, antisense DNA and ribozyme in Class 3. According to the principle of complementary bases, the use of a specific sequence complementary to the target gene short-chain DNA fragment to be closed target gene expression, or the use of ribozymes with their corresponding mRNA degradation, can achieve the purpose of gene therapy. Wang et al [1] by AFP antisense oligonucleotide treatment in vitro and The SMMC 7721 HCC model in nude mice achieved significant antitumor effect, reducing the expression of AFP, inhibit the proliferation of SMMC 7721 cells. Studies have shown [2], the reference regimen of antisense insulin growth factor (Insulingrowth fa